about
Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-NetCell(s) of Origin of Langerhans Cell HistiocytosisConsensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseEarly-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutationsIntracranial plasma cell granuloma: case report and treatment of recurrence with methotrexate and 6-mercaptopurine.Expression profiling using human tissues in combination with RNA amplification and microarray analysis: assessment of Langerhans cell histiocytosis.Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry.Aseptic meningitis in a child after systemic treatment with high dose cytarabine.Hemophagocytic lymphohistiocytosis associated with precursor B acute lymphoblastic leukemia.Bone marrow involvement in histiocytosis X.Childhood idiopathic thrombocytopenic purpura: association with human parvovirus B19 infection.Central nervous system disease in Langerhans cell histiocytosis.Pediatric Burkitt's lymphoma and diffuse B-cell lymphoma: are surveillance scans required?fHLH: becoming a blended family.Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society.Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease.Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia.Epstein-Barr virus and HIV-AIDS-associated diseases.Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.Differentiating skin-limited and multisystem Langerhans cell histiocytosis.Need for a cooperative study: Pulmonary Langerhans cell histiocytosis and its management in adults.Adult Langerhans cell histiocytosis limited to the skin.Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease.Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis.How I treat Langerhans cell histiocytosis.Drug therapy for the treatment of Langerhans cell histiocytosis.Pediatric Hodgkin lymphoma: are we over-scanning our patients?Histiocytic disorders: recent insights into pathophysiology and practical guidelines.BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.Ribosomal binding sites on poliovirus RNA.A 2-year-old with 4 weeks of daily fever.Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis.PET/MR in the Assessment of Pediatric Histiocytoses: A Comparison to PET/CT.Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma.Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study.Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone?A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults.Hemophagocytic lymphohistiocytosis in a patient with x-linked lymphoproliferative disease.Prolongation of the prothrombin time after organophosphate poisoning.
P50
Q21202846-228D038E-0683-4E64-9E73-1E77B7E21EE9Q28087231-5F1F8429-F359-4C33-B0C7-A9E7E7D18105Q28240576-F8892343-3408-42EF-8D89-77C58F8731ACQ28250725-6B59D255-70D4-411A-BCA8-2124A86EFD86Q31017786-B8EAD856-6A04-401C-88F3-9F916FD17EF7Q31156227-0CCC04BF-8C08-4A01-B4E0-976FFCD84E92Q31160903-00F567AD-B97B-423D-859D-CEC1003E2EECQ31931486-F79BFC4E-0B31-4126-99FC-791B5FA022FCQ33394019-6D212274-BE90-408B-9F13-D11C76BE131FQ33479805-F6590C56-0ED0-4190-A692-24FA102BC590Q33491292-662672FD-F2CE-4320-9F6E-7BBF967A192AQ33569491-671B072A-8FA9-443E-B36A-C9684726B18BQ34047346-685924DA-3132-403B-9808-8E5E040A7C13Q34077762-CE469195-1D32-4A58-9780-98B8B5C5C161Q34269591-72B1D617-1697-46B9-B6D2-096608C2D311Q34328662-1A36A078-479C-431A-A426-91E6190B13F9Q34371730-5B5E11E4-F941-4ECE-9A73-7B0DA8F60D04Q34415880-1EB1284F-B94C-4FF9-92C2-0B5339C82B9CQ34471813-6B5B12F8-0B8E-4EBD-9A80-68214B60ACBCQ34561113-D3AE3EDD-7E53-44CC-BE4D-2F96C2833479Q34624753-ECF135C3-5537-4DAA-AC5D-6999CAAF641DQ34737167-842C1730-18A7-4695-B96B-7056121708A9Q35200443-04FEE1BC-7520-43FE-8132-8D5FE9F540F9Q35761309-7E788181-9FC2-4849-8503-C1633323C5B0Q35788460-9B6F64DF-1407-4A0F-AAAC-B96A2F28004CQ35820361-6B69B5EC-DF73-44C7-BB7C-1EA6B94C131FQ36301581-EC3D3C85-C815-4303-B44D-766F76546EFAQ36937181-E5083E56-845C-4C0E-A1D7-9F8C6EA91012Q37637252-6780158E-AF75-4D76-A53C-7F2A14864C4AQ37689383-03D57BB5-D7DE-4D67-AB32-FF888361C414Q38356170-B264A4C6-E34B-4558-BDB3-F5004D0EB8B5Q38445620-F5AA0B1C-7E7F-4597-87EB-88E0A3182CD9Q38659467-51C1704C-3C57-4323-8536-2D5EA91B573DQ38730534-D422187A-85FF-454C-B8FF-24A7572E8F0AQ38781872-5D45E10C-ABF4-442E-B52C-AA8C6A5A99C6Q38789575-356A21F4-797E-40F5-ADB3-654E9BD63056Q39004395-B5E3635A-4382-4543-A684-A39B08D72234Q39378276-AB497BED-0A34-45C2-9101-3ED8E7710E48Q40379278-BD8A1BE7-8CF4-47FC-A73B-9CB6F8155030Q40585757-72A317AE-A77C-4407-B44B-9D36EEBC1884
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kenneth L McClain
@ast
Kenneth L McClain
@en
Kenneth L McClain
@es
Kenneth L McClain
@nl
type
label
Kenneth L McClain
@ast
Kenneth L McClain
@en
Kenneth L McClain
@es
Kenneth L McClain
@nl
prefLabel
Kenneth L McClain
@ast
Kenneth L McClain
@en
Kenneth L McClain
@es
Kenneth L McClain
@nl
P106
P31
P496
0000-0003-0725-6263